Effects of prostaglandin E1 on the progression of aristolochic acid nephropathy.
- Author:
Dong SUN
1
;
Jiang-min FENG
;
Yan-ling ZHAO
;
Tao JIN
;
Li-ning WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Alprostadil; therapeutic use; Aristolochic Acids; adverse effects; Creatinine; blood; Female; Follow-Up Studies; Hemoglobins; metabolism; Humans; Kidney; pathology; Male; Middle Aged; Nephritis, Interstitial; chemically induced; drug therapy; pathology
- From: Chinese Medical Sciences Journal 2005;20(1):67-69
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo investigate the effects of prostaglandin E1 (PGE1) on the progression of aristolochic acid nephropathy (AAN).
METHODSTwenty-four patients diagnosed as AAN with serum creatinine (Scr) between 1.5 mg/dL and 4 mg/dL during September 2001 to August 2003 were randomly divided into 2 groups. All patients had ingested long dan xie gan wan containing aristolochic acid (0.219 mg/g) for at least 3 months. Twelve patients were injected with Alprostadil (10 microg/d for 10 days in one month, summing up to 6 months). Except for PGE1, the other therapy was same in both groups. Renal function was assessed using reciprocal serum creatinine levels (1/Scr).
RESULTSThe level of Scr an d serum hemoglobin (Hgb) was similar in both groups prior to therapy. During follow-up, 1/Scr levels in PGE1 group were significantly higher than control group (P < 0.01), and Hgb levels in PGE1 group were significantly increased compared with control (P < 0.05).
CONCLUSIONPGE1 can slow the progression of renal failure and increase Hgb level of AAN patient.
